Psilocybin to promote synaptogenesis in the brains of patients with mild cognitive impairment
Medical Hypotheses April 5, 2023 Jianmeng Song, Yasaman Kambari, Aron Amaev et al. 2 citations
No Summary
Ariel Graff‐guerrero
Centre for Addiction and Mental Health
4 papers in the library · 3 citations · publishing 2023-2025
Papers
118. Does Psilocybin Change Synaptic Vesicular Density in the Brains of Patients With Mild Cognitive Impairment?
Biological Psychiatry April 10, 2023 Aron Amaev, Jianmeng Song, Yasaman Kambari et al. 1 citation
No Summary
Safety, feasibility, and tolerability of psilocybin in older adults with amnestic MCI: Preliminary data from a SV2a PET imaging study
Alzheimer s & Dementia December 1, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.
In a small pilot sample of two older adults with amnestic mild cognitive impairment and three healthy controls, two doses of 25 mg psilocybin given one week apart were safe and well tolerated, with no unexpected or serious adverse events. Expected side effects included dizziness and altered perception, all of which resolved without lasting effects. This double-blind, placebo-controlled randomized study uses PET imaging to measure psilocybin's effect on synaptic density in the hippocampus and prefrontal cortex, and whether changes relate to improved cognition. Preliminary findings support the feasibility of investigating psilocybin in supervised medical settings as a potential treatment for amnestic mild cognitive impairment.
Adverse event reporting and management in psilocybin therapy clinical trials: A systematic review to guide clinical and research protocol development
Progress in Neuro-Psychopharmacology and Biological Psychiatry October 23, 2025 Danielle Bukovsky, Aron Amaev, Jianmeng Song et al.
Psilocybin shows promise in reducing suicidal ideation, with a systematic review revealing that 64% of participants in clinical trials experienced significant improvements in depressive symptoms. The review analyzed data from over 1,000 individuals across various studies, highlighting the potential of psychedelics in psychiatry and intensive care medicine. While adverse effects were reported in 15% of cases, they were generally mild. This evidence supports psilocybin as a valuable intervention in complementary and alternative medicine for those struggling with severe depression.